Core Viewpoint - The Munich Regional Court has ruled that Merck & Co.'s Keytruda SC is facing imminent infringement issues in Germany related to Halozyme's MDASE patents in Europe [1] Company Summary - Merck & Co. is currently dealing with legal challenges regarding its Keytruda SC product in Germany [1] - Halozyme has asserted its MDASE patents in Europe, which has led to the court's ruling against Merck & Co. [1] Industry Summary - The ruling highlights ongoing patent disputes within the pharmaceutical industry, particularly concerning immunotherapy products [1] - The case underscores the importance of patent protection and intellectual property rights in the competitive landscape of drug development [1]